Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

You may be eligible if

• A clinical diagnosis of definite, probably or laboratory supported probably ALS, either sporadic or familial ALS according to a modified El Escorial criteria
• Willing and able to give informed consent
• FVC greater than or equal to 50% predicted
• Evidence of abnormality in upper and/or lower extremity motor function (clinical evidence of muscle atrophy and weakness in an upper and/or lower extremity). The patient should have at least 4 or 8 testable upper extremity muscle groups.
• Subjects may take riluzole. Riluzole must have been at stable doses for at least thirty days prior to baseline visit.
• If woman of childbearing age, must be non-lactating and surgically sterile or using an effective method of birth control (double barrier or oral contraceptive) and have a negative pregnancy test
• Disease duration less than five years